THYROCARE - Thyrocare Technologies Limited Share Price

Key Q&A from Thyrocare's Q3 FY '26 Earnings Call

Question 1: Would it be fair to say that you have a huge lead in your B2B offering compared to others? I believe we have a significant competitive advantage due to two key factors. Firstly, we have a dedicated fleet of 2,000 phlebotomists servicing corporate partnerships, enhancing control over service quality. Secondly, our technology platform allows seamless diagnostics orders across 400 cities with API integration, making our value proposition quite compelling in the B2B space.

Question 2: What has caused the recent uptick in PharmEasy's business with you, and is it sustainable? While we don't rely solely on PharmEasy's growth, their focus on diagnostics alongside medicine bodes well for sustained growth. Their overall growth trajectory in health tech suggests a good level of growth in our partnership with them, particularly as diagnostics is central to their strategy.

Question 3: Why did Vimta's business experience degrowth during the quarter? When do you expect normalization? Vimta has seen a degrowth due to tightened credit policies compared to Thyrocare's prepaid model. We expect this to normalize moving forward and anticipate seeing consistent growth thereafter.

Question 4: What is the revenue recognition difference between the franchisee and partnership models? In the franchisee model, we recognize our revenue through a fixed rate per test sold, while in partnerships, we recognize the entire amount billed to patients. Subsequently, we share commission with our partners, but our revenue recognition reflects the total.

Question 5: Given your growth rate has dipped below 20%, will this be the norm going forward? Our long-term growth guidance stands at mid-teens due to the high base effect. Although we've exceeded this in recent quarters, I'm cautious going forward, aiming for sustainable growth rather than rapid spikes that may not be maintainable.

Question 6: Can we achieve a 15% to 16% growth over the next two years and improve margins? Achieving 15% growth is realistic, albeit at a cost. While we don't foresee margin expansion, we do not expect them to dilute significantly either. Our focus remains on sustainable growth while investing in specialty offerings.

Question 7: How do you foresee growth in the partnership model? How sustainable is it? We anticipate a long-term growth rate for partnerships that could be 1.5 times that of our franchise business growth. This model benefits from the increasing integration of health tech players into diagnostics, which creates a favorable environment for our sustained growth.

Question 8: What are your expectations from the Tanzania operations? Tanzania is currently a nascent market for us. We project revenues around INR 3 crores this year, with the business doubling annually. While promising, we want to solidify our presence before exploring further expansion in Africa.

Question 9: What is your current depreciation charge and capital expenditure? This quarter, we have experienced an increase in depreciation due to ROU capitalizations. We expect total capital expenditures to be around INR 28 to 30 crores thus far this financial year, including INR 20 to 22 crores related to ROU assets.

Question 10: What pricing strategy is followed in the partnership business? Pricing is flexible; partners can set their own prices based on our minimum guidelines. Our invoicing policy is based on volumes, which allows partners to adjust pricing as needed based on their commercial model.